Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Viral origins, evolution and diversity
  • Track 1-2Viral fitness and resistance
  • Track 2-1Chlamydia
  • Track 2-2Genital Herpes
  • Track 2-3Human Papillomavirus (HPV)
  • Track 2-4Syphilis
  • Track 2-5Viral Hepatitis
  • Track 2-6Bacterial Vaginosis
  • Track 2-7Trichomoniasis
  • Track 3-1Bacterial Vaginosis
  • Track 3-2Herpes
  • Track 3-3Nongonococcal Urethritis
  • Track 3-4Lymphogranuloma Venereum
  • Track 4-1Innate immunity
  • Track 4-2Humoural immunity
  • Track 4-3Cellular immunity
  • Track 4-4Mucosal immunity
  • Track 5-1Cell-based preventative vaccines
  • Track 5-2Adjuvants
  • Track 5-3Therapeutic vaccines
  • Track 6-1Antimicrobial drug resistance
  • Track 6-2Poor treatment adherence
  • Track 6-3Varying pharmacokinetics
  • Track 6-4Antiretroviral therapy
  • Track 7-1Pathogenesis
  • Track 7-2Virulence factors
  • Track 7-3Host susceptibility or resistance
  • Track 7-4Immune mechanisms
  • Track 7-5Immune mechanisms
  • Track 7-6Targets for vaccine design
  • Track 8-1Microbial diversity of healthy humans
  • Track 8-2Microbiome metabolism and function
  • Track 8-3Correlations with host phenotype
  • Track 9-1Menopause and HIV
  • Track 9-2Contraception and HIV
  • Track 9-3Contraception and HIV
  • Track 9-4Safe conception for serodiscordant couples
  • Track 10-1Premature birth
  • Track 10-2Genetic disorder
  • Track 10-3Poor growth
  • Track 10-4Mental retardation
  • Track 11-1Reducing pre-partum and intra-partum transmission to infants
  • Track 11-2Reducing post-partum transmission in infants
  • Track 11-3Integration of family planning
  • Track 12-1HIV-exposed uninfected children
  • Track 12-2Clinical trials in children and adolescents
  • Track 12-3Therapeutic drug monitoring in paediatric population
  • Track 12-4Drug formulations for infants and children
  • Track 13-1Novel assays of immune responses
  • Track 13-2Animal Models
  • Track 13-3HIV testing
  • Track 13-4HIV testing
  • Track 13-5Diagnostics of co-infections and comorbidities
  • Track 13-6Drug resistance testing
  • Track 14-1Neurologic disorders
  • Track 14-2Neurologic disorders
  • Track 14-3Depression and other psychiatric manifestations
  • Track 14-4Depression and other psychiatric manifestations
  • Track 14-5AIDS and non-AIDS malignancies
  • Track 14-6Lipodystrophy and hyperlipidaemia
  • Track 14-7Cardiovascular disease
  • Track 16-1HIV controllers
  • Track 16-2Correlates of immune protection
  • Track 16-3Proper Education and Awareness of STDs
  • Track 16-4Antifungal, antibacterial and antiviral diet
  • Track 17-1Preclinical drug development
  • Track 17-2Targeting HIV persistence during ART
  • Track 17-3Nucleic acid-based HIV therapies
  • Track 17-4Immunotherapy
  • Track 19-1 Kaposi sarcoma
  • Track 19-2Cervical Cancer
  • Track 19-3Non-Hodgkin lymphoma
  • Track 20-1Safer sex
  • Track 20-2Risk at Sex workers
  • Track 20-3HIV prevention programmes for sex workers